Literature DB >> 12453985

Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.

Yoshinori Mitamura1, Asako Tashimo, Yasushi Nakamura, Hiroshi Tagawa, Kenji Ohtsuka, Yuka Mizue, Jun Nishihira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12453985     DOI： 10.2337/diacare.25.12.2352

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  17 in total

1.  Human retinal epithelium produces and responds to placenta growth factor.

Authors:  Margrit Hollborn; Solveig Tenckhoff; Marlen Seifert; Stephanie Köhler; Peter Wiedemann; Andreas Bringmann; Leon Kohen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-09       Impact factor: 3.117

2.  Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.

Authors:  E Al Kahtani; Z Xu; S Al Rashaed; L Wu; A Mahale; J Tian; E B Abboud; N G Ghazi; I Kozak; V Gupta; J F Arevalo; E J Duh
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

3.  Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.

Authors:  Chuan Sun; Hongsong Zhang; Jingjing Jiang; Yuxin Li; Chuang Nie; Jianwen Gu; Ling Luo; Zhijun Wang
Journal:  Int Ophthalmol       Date:  2019-12-04       Impact factor: 2.031

4.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

5.  Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy.

Authors:  Laura Kowalczuk; Elodie Touchard; Samy Omri; Laurent Jonet; Christophe Klein; Fatemeh Valamanes; Marianne Berdugo; Pascal Bigey; Pascale Massin; Jean-Claude Jeanny; Francine Behar-Cohen
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

6.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

7.  Aflibercept versus ranibizumab for treating persistent diabetic macular oedema.

Authors:  Kristof R O A Vandekerckhove
Journal:  Int Ophthalmol       Date:  2015-05-20       Impact factor: 2.031

Review 8.  Diabetic Retinopathy: Vascular and Inflammatory Disease.

Authors:  F Semeraro; A Cancarini; R dell'Omo; S Rezzola; M R Romano; C Costagliola
Journal:  J Diabetes Res       Date:  2015-06-07       Impact factor: 4.011

9.  Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1α-VEGF pathway inhibition.

Authors:  Hu Huang; Jianbo He; Da'Kuawn Johnson; Yanhong Wei; Ying Liu; Shuang Wang; Gerard A Lutty; Elia J Duh; Richard D Semba
Journal:  Diabetes       Date:  2014-09-03       Impact factor: 9.461

10.  Vitreous levels of vascular endothelial growth factor, stromal cell-derived factor-1α, and angiopoietin-like protein 2 in patients with active proliferative diabetic retinopathy.

Authors:  Ali Keles; Kenan Sonmez; Yasemin Ozdamar Erol; Sema Nur Ayyıldız; Elmas Ogus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-19       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.